{
    "id": "3b1267fd-ecfa-416f-969c-d601fa5b84a1",
    "indications": "LYRICA CR is indicated for the management of:\n                  \n                     \n                        •Neuropathic pain associated with diabetic peripheral neuropathy\n                     \n                        •Postherpetic neuralgia\n                  \n                  Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.",
    "contraindications": "• LYRICA CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed. ( 2.1 ) • Dosing recommendations for LYRICA CR: Indication Dosing Regimen Initial Dose Maximum Dose DPN Pain ( 2.2 ) Single dose per day 165 mg/day 330 mg/day within 1 week. PHN ( 2.3 ) Single dose per day 165 mg/day 330 mg/day within 1 week. Maximum dose of 660 mg/day. • Conversion from LYRICA Capsules or Oral Solution to LYRICA CR: See full prescribing information. ( 2.4 ) • Dose modification recommended in patients with renal impairment. ( 2.5 )",
    "warningsAndPrecautions": "LYRICA CR is supplied in the following strengths and package configurations:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 LYRICA CR Tablets\n                              \n                           \n                        \n                        \n                           \n                              \n                                 Package Configuration\n                              \n                           \n                           \n                              \n                                 TabletStrength (mg)\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                           \n                        \n                        \n                           \n                              Bottles of 30 tablets\n                           \n                           \n                              82.5 mg\n                           \n                           \n                              NDC 58151-245-93\n                           \n                           \n                              Light blue, film-coated, almond-shaped tablet debossed with “VLE” on one side and “PGN 82.5” on the other side\n                           \n                        \n                        \n                           \n                              Bottles of 30 tablets\n                           \n                           \n                              165 mg\n                           \n                           \n                              NDC 58151-246-93\n                           \n                           \n                              Beige, film-coated, almond-shaped tablet debossed with “VLE” on one side and “PGN 165” on the other side\n                           \n                        \n                        \n                           \n                              Bottles of 30 tablets\n                           \n                           \n                              330 mg\n                           \n                           \n                              NDC 58151-247-93\n                           \n                           \n                              Rose, film-coated, almond-shaped tablet debossed with “VLE” on one side and “PGN 330” on the other side\n                           \n                        \n                     \n                  \n                  Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F) in the original package. (See USP Controlled Room Temperature)",
    "adverseReactions": "LYRICA CR is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.1, 5.2), Adverse Reactions (6)].",
    "ingredients": [
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M"
        },
        {
            "name": "CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE",
            "code": "0A5MM307FC"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "KOLLIDON SR",
            "code": "S34RY76LK6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "organization": "Viatris Specialty LLC",
    "name": "Lyrica CR",
    "effectiveTime": "20250409"
}